

# Autonomous Screening for Diabetic Macular Edema Using Deep Learning Processing of Retinal Images

Idan Bressler [1], Rachelle Aviv [1], Danny Margalit [1], Gal Yaakov Cohen MD [2, 3], Tsoncho Ianchulev, MD MPH [1, 4], Shravan V. Savant, MD [5,6], David J. Ramsey, MD PhD [5,6], Zack Dvey-Aharon, PhD [1]

[1] AEYE Health Inc.

[2] The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel

[3] Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

[4] New York Eye and Ear, Mount Sinai Hospital, NY

[5] Department of Ophthalmology, Lahey Hospital & Medical Center, Peabody, MA

[6] Department of Ophthalmology, Tufts University School of Medicine, Boston, MA

## Abstract

**Background:** Diabetic Macular Edema (DME) is a complication of diabetes which, when untreated, leads to vision loss. Screening for signs of diabetic eye disease, including DME, is recommended for all patients with diabetes at least every one to two years, however, compliance with this standard is low.

**Methods:** A deep learning model was trained for DME detection using the EyePACS dataset. Data was randomly assigned, by participant, into development (n= 14,246) and validation (n= 1,583) sets. Analysis was conducted on the single image, eye, and patient levels. Model performance was evaluated using sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC). Independent validation was further performed on the IDRiD dataset, as well as new data.

**Findings:** At the image level, sensitivity of 0.889 (CI 95% 0.878, 0.900), specificity of 0.889 (CI 95% 0.877, 0.900), and AUC of 0.954 (CI 95% 0.949, 0.959) were achieved. At the eye level, sensitivity of 0.905 (CI 95% 0.890, 0.920), specificity of 0.902 (CI 95% 0.890, 0.913), and AUC of 0.964 (CI 95% 0.958, 0.969) were achieved. At the patient level, sensitivity of 0.901 (CI 95% 0.879, 0.917), specificity of 0.900 (CI 95% 0.883, 0.911), and AUC of 0.962 (CI 95% 0.955, 0.968) were achieved.

**Interpretation:** DME can be detected from color fundus imaging with high performance on all analysis metrics. Automatic DME detection may simplify screening, leading to more encompassing screening for diabetic patients. Further prospective studies are necessary.

**Funding:** Funding was provided by AEYE Health Inc.

## Introduction

Diabetic Macular Edema (DME) is a complication of diabetes mellitus, closely associated with diabetic retinopathy (DR).<sup>1</sup> DME is characterized by the accumulation of excess fluid in the extracellular space within the central macula,<sup>2,3</sup> and when untreated ultimately leads to vision loss due to damage to the microvasculature and photoreceptors of the fovea, which is responsible for high-resolution visual acuity. DME has a major impact on public health, affecting approximately 3.8% of the population<sup>4</sup> with an incidence of more than 25% within 25 years of diagnosis of type 1 diabetes mellitus (T1DM)<sup>5</sup> and 25% within nine years of the diagnosis of type 2 diabetes mellitus (T2DM).<sup>6</sup>

The Early Treatment Diabetic Retinopathy Study (ETDRS) defined clinically significant macular edema (CSME) with specific anatomic criteria which include retinal thickening or the presence of hard exudates within 500  $\mu\text{m}$  of the fovea.<sup>7</sup> Interventions studied in the ETDRS treatment protocol, such as focal laser photocoagulation and intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, have shown significant improvement in visual acuity and prognosis after treatment.<sup>8-10</sup> Therefore, early detection and intervention are crucial in providing the opportunity to achieve good patient outcomes.

It is recommended that all patients with diabetes are screened for DME every 1 to 2 years.<sup>11,12</sup> Screening is conducted as a part of regular screening and management for DR, and typically involves slit lamp examination of the dilated fundus or the use of color fundus photography.<sup>11</sup> While the diagnosis of DME is traditionally based on fundus photography and fluorescein angiography, optical coherence tomography (OCT) has increasingly been used to quantitate the extent of diabetes-related retinal thickening.<sup>13,14</sup> This modality is expensive, however, and generally available only at specialized eye clinics that can afford this technology; as such, it is not widely accessible for primary screening purposes. Thus, screening for DME continues to be performed by detecting classic patterns of findings in color fundus imaging, namely exudates and associated macular thickening.<sup>10,15,16</sup>

Access and scalability are crucial elements of any population-health screening program. The need for a specialized eye examination and sophisticated equipment have been significant obstacles for streamlined DME screening, causing many patients to remain undiagnosed.<sup>17-20</sup> Machine learning and deep learning algorithms are ideal tools to address this limitation and empower an efficient and exponential screening process at the level of non-specialized, primary care delivery.<sup>21-23</sup>

Methods for DR screening using deep learning algorithms which examine fundus images have shown promising results.<sup>24,25</sup> Furthermore, autonomous DR screening has received FDA

approval,<sup>26</sup> opening the door to the implementation of further similar applications, such as DME screening. While OCT-based machine learning methods have shown good results in detection of DME,<sup>27–29</sup> with some methods boasting almost 100% accuracy, the cost and limited availability of OCT technology limits its ability to be used as a screening tool on a large scale.

Other fundus imagery-based methods which focus primarily on exudate detection were previously developed,<sup>30–34</sup> as have been methods based on the entire CSME criteria.<sup>35,36</sup> This study will expand on these works by being validated on multiple datasets, from multiple locations and using multiple definitions for CSME, showing good agreement with all of them. Furthermore, not only does the model developed exhibit excellent CSME detection, it does so at the patient level rather than by eye, making this work more clinically relevant from a functional screening standpoint.

## Methods

### Data

The main dataset utilized for training and validation was compiled and provided by EyePACS<sup>37</sup> and consisted of 45° angle fundus photography images and expert readings of said images. All images and data were de-identified according to the Health Insurance Portability and Accountability Act “Safe Harbor” before they were transferred to the researchers. This study was conducted in compliance with the tenets of the Declaration of Helsinki and institutional review board exemption was obtained.

The EyePACS dataset contained up to six images per patient visit: one macula centered image, one disk centered image and one centered image per eye (in which a central fixation image is fixated on the middle of a line connecting the foveola and the optic disc). Each eye underwent expert reading, which included but was not limited to detecting the presence of DME, grading the level of DR, and assessing the image quality. It should be noted that this quality assessment was based on the overall readability of a given eye and does not guarantee that all images of an eye were of the same quality. Images deemed unreadable by an expert were omitted from our analysis, as were disc-centered images, because these provide only a limited view of the macula.

The method used to determine the presence of CSME in fundus images in the vast majority of the EyePACS dataset was Bresnick's criterion,<sup>38</sup> which is defined as the existence of hard exudates within one disc diameter from the center of the macula. A different method used in a minority of the dataset was the criterion presented in Litvin et al;<sup>39</sup> this defined CSME by dividing the macula into an eight sector “pie” within one disc diameter of the center of the macula. If three sectors of the pie have hard exudates, or if hard exudates are present within 1/3 of a disc diameter from the center the macula, it was graded to have likely CSME.

A comprehensive dataset for the purposes of training, validation, and testing was constructed from the EyePACS dataset, consisting of 32,049 images from 15,892 patients. Up to two

images were taken for each eye from two different fields, one centered on the macula and another centered between the macula and the disc. The average age was 55.02 (10.21 SD), and 51% of the patients were female (**Table 1**). **Table 2** shows the distribution of DME patients across DR levels; DME was only present for patients with more than mild DR (mtmDR), with approximately 49% of all images being DME positive. Additional statistics are given in **supplementary tables 1-2**

An additional dataset used for validation was the Messidor-2 dataset,<sup>40</sup> also containing 45° angle fundus photography images and expert annotations for DME presence and DR level. The dataset consisted of 1748 macula-centered images from 874 examinations, of which 151 images (8.6%) were DME positive. Additional information is provided in **supplementary table 3**.

External validation was further performed on the IDRiD dataset, as well as a dataset comprised of patient images from Lahey Hospital and Medical Center.

## Pre-Processing

Image pre-processing was performed in two steps. First, the image background was cut along the convex hull which contains the circular border between the image and the background. **Figure 1** shows an example result of this process. Secondly, each image was resized to 512 X 512 pixels.

## Quality assessment

A tool for image quality assessment was developed. The tool gives a quality score for an image using an aggregation of the visibility score from multiple areas within the fundus image. **Figure 2** demonstrates a few examples of images and their respective scores, showing the correlation between score and visual image quality.

## Model training

The data was divided into training, validation, and test datasets consisting of 80%, 10%, and 10% of the data respectively.

A binary classification neural network was trained. The model architecture was automatically fitted to best balance the model performance vs model complexity tradeoff. Hyperparameter tuning was done using the validation set.

A total of 1,978 images were filtered out (approximately 6.2% of the data).

## Statistical analysis

The metrics used for assessment were accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). For each metric the bias corrected and accelerated bootstrap method<sup>41</sup> was used to produce a 95% confidence interval.

## Analysis levels

DME detection was done on three different levels. The first level assessed detection at the level of each individual image, which was the basic task for which the model was trained. The second level was detection for each eye, using both macula-centered and mid-disc/macula centered image fields for a given eye. This method is akin to fundus-photo-based detection of DME performed by a human expert. In this approach the best image for each eye (in terms of image quality as assessed by the image quality tool) was selected for analysis. The third level was the patient level. For clinical purposes, detection of DME in one eye is sufficient for referral to further checks; as such, the “worst of two eyes” approach was used.

## External Validation

The module was further validated by two external teams. The first external validation set was “real-world” data collected from 50 patients with DR at the Lahey Hospital and Medical Center. Of these patients, 19 had DME confirmed by OCT and 31 did not. One macula-centered image was selected from each eye for analysis, and the evaluation was done by an ophthalmologist based on Bresnick’s method. DME detection analysis was then performed on all images using the proposed model. Performance was judged using the metrics mentioned above.

The assessment for the second external validation was conducted by an MD of The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, using the IDRiD training dataset,<sup>42</sup> which is comprised of 400 macula-centered images. DME/CSME detection were performed based on the method presented in Wong et al,<sup>43</sup> in which DME is defined via the existence of hard exudates one disc diameter from the macula and CSME is defined via the existence hard exudates 500  $\mu$ m from the macula. The data was first annotated into three categories: DME positive (235), DME negative (142), and unreadable (23), and DME detection analysis was then performed on all readable images using the proposed model. Comparison was done using the metrics mentioned above.

## Results

### EyePACs dataset

The results for the different analysis methods were as follows (**table 3**), (confidence intervals set to 95% in parentheses): on the image level, sensitivity of 0.889 (0.878, 0.900) and specificity of

0.889 (0.877, 0.900) were achieved. On the eye level, sensitivity of 0.905 (0.890, 0.920) and specificity of 0.902 (0.890, 0.913) were achieved. On the patient level, sensitivity of 0.901 (0.879, 0.917) and specificity of 0.900 (0.883, 0.911) were achieved.

The results for each DR level for which DME is present are displayed in **table 4**, showing comparable results across all DR levels. The model achieved 0.958 AUC (0.952, 0.964) for DR level 2, 0.935 AUC (0.923, 0.945) for DR level 3, 0.940 AUC (0.926, 0.952) for DR level 4, and 0.954 AUC (0.919, 0.975) for ungradable DR level. DR grades 0 and 1 did not have any DME positive examples; thus, most metrics are not defined for these grades; the model achieved an accuracy of 0.981 and 0.876 (CI not defined) respectively.

**Table 5** shows the results for images which passed (high quality) and didn't pass (low quality) the quality filter, showing significant differences between the populations. The results for images which were filtered out were 0.671 sensitivity (0.599, 0.737), 0.843 specificity (0.790, 0.886), and 0.853 AUC (0.811, 0.887). Results for images which passed the quality filter were 0.902 sensitivity (0.892, 0.912), 0.883 specificity (0.871, 0.893), and 0.956 AUC (0.952, 0.961) for images that passed the filter. The filter allowed for a reading on the patient level of 98% of the patient cohort.

## Messidor-2 dataset

Messidor-2 contained readings for the image and patient levels, containing one image per eye. The results on this data set were an AUC of 0.971 (0.955 - 0.982), 0.875 sensitivity (0.811 - 0.922), and 0.954 specificity (0.939 - 0.967), surpassing previous works (**table 6**). On the patient level an AUC of 0.964 (0.936, 0.979), sensitivity of 0.897, (0.820, 0.947) and specificity of 0.932 (0.905, 0.953) were achieved.

## External Validation Datasets

When tested on the first validation dataset of 100 images, the model achieved 0.880 accuracy (0.757, 0.955), 0.789 sensitivity (0.544, 0.939), and 0.935 specificity (0.786, 0.992).

When tested on the second, larger validation dataset of 413 images, 23 were labeled as unreadable. Performance of the model on the remaining 377 images demonstrated 0.854 (0.812, 0.883) accuracy, 0.851 (0.802, 0.893) sensitivity, 0.859 (0.794, 0.909) specificity and 0.931 (0.900, 0.953) AUC.

## Discussion

This work introduces a novel, proprietary autonomous system for the detection of DME from fundus images. This may shorten and simplify the screening processes and allow for wider screening of DME. Given the short (within three months) recommended referral time after DME



detection,<sup>11</sup> and the potential threat to patients' vision if left untreated, the widespread use of autonomous screening has the potential to be of clinical importance.

The need to screen for DME independently from autonomous DR screening stems from three main factors. Firstly, the recommended referral time for DME is shorter than that of most DR cases without DME.<sup>11</sup> Secondly, the treatment regime for DME differs from that of DR without DME,<sup>44</sup> emphasizing the importance of distinguishing DME cases from DR cases. Third, the effect of DME is usually more visually significant than DR and has a higher risk of causing irreversible vision changes.<sup>45</sup>

This work demonstrated good results on multiple validation datasets, from multiple locations and with different definitions for CSME. This expands on previous works by showing robustness in multiple different settings and across definitions used, demonstrating the applicability and general usability of this method.

This work proposed analyzing DME on multiple levels, expanding on existing works which focused on the single image level, and shows higher efficacy on the image level as compared to previous studies. Additionally, it showed comparable results between the Messidor-2 dataset and the less curated (in terms of image quality) EyePACS dataset, demonstrating its robustness across different image qualities. The model can produce results for the vast majority of examined patients, further supporting the possible widespread capabilities and applications.

Analysis on the eye level, i.e., analyzing a single eye with multiple images of the same eye, may be more accurate and representative of clinical practice than image-level analysis. When multiple fields of the same eye exist, experts label images based on the integration of present information. This may lead to the labeling of individual images being misleading, especially if differences in image quality exist. For instance, an eye that appears healthy from one angle, often due to low image quality, might have visible DME at another angle, leading to a seemingly healthy image being positively labeled. The presented eye-level analysis tackles this issue by selecting the highest quality field from each eye.

The final model presented, which performs an analysis on the patient level, may be more clinically relevant than reporting findings at the single image or eye levels because the clinical criterion for referral is the existence of DME on the patient level. This method demonstrated high (~90%) sensitivity and specificity.

CSME with foveal involvement is also known as CMSE with center involvement (CSME-CI),<sup>2,11</sup> and the ability of graders to consistently detect this has been questioned.<sup>46</sup> Despite CSME-CI being more severe, all CSME cases are referable and detection of CSME remains common clinical practice and a referral marker, thus making widespread screening of CSME important. This paper therefore focuses on CSME detection and not CSME-CI detection.

This work has a few limitations. Firstly, model training was performed on the single image level, thus hindering the training with the aforementioned image labeling problem. Secondly, the two methods used for ground truth may not be as accurate as a comprehensive eye exam using

OCT in addition to the color fundus images. Finally, some of the methods used for ground truth may have underlying limitations; for example, one retrospective study examining the Bresnick method showed low specificity versus a more established ground truth (ETDRS). However, by definition, any patient with more than mild DR should be referred and most patients who have findings that meet the Bresnick criterion would qualify on this basis.

## Bibliography

- 1 Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. *JAMA* 2007; **298**: 902–16.
- 2 Lang GE. Diabetic Macular Edema. *OPH* 2012; **227**: 21–9.
- 3 Bandello F, Parodi MB, Lanzetta P, *et al.* Diabetic Macular Edema. In: Macular Edema. Karger Publishers, 2010: 73–110.
- 4 Varma R, Bressler NM, Doan QV, *et al.* Prevalence of and risk factors for diabetic macular edema in the United States. *JAMA Ophthalmol* 2014; **132**: 1334–40.
- 5 Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy XV. *Ophthalmology* 1995; **102**: 7–16.
- 6 White NH, Sun W, Cleary PA, *et al.* Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. *Diabetes* 2010; **59**: 1244–53.
- 7 Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie house classification. *Ophthalmology* 1991; **98**: 786–806.
- 8 Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, *et al.* Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010; **117**: 1064-1077.e35.
- 9 Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY. Treatment of Diabetic Macular Edema. *Curr Diab Rep* 2019; **19**: 68.
- 10 Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. *Surv Ophthalmol* 2009; **54**: 1–32.
- 11 International Diabetes Federation. Clinical Practice Recommendations for Managing Diabetic Macular Edema. Brussels, Belgium: International Diabetes Federation, 2019 <https://www.idf.org/e-library/guidelines/161-dme-clinical-practice-recommendations.html>.
- 12 American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, *et al.* Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. *Diabetes Care* 2022; **45**: S185–94.
- 13 Panozzo G, Parolini B, Gusson E, *et al.* Diabetic macular edema: an OCT-based classification. *Semin Ophthalmol* 2004; **19**: 13–20.



- 14 Panozzo G, Gusson E, Parolini B, Mercanti A. Role of OCT in the diagnosis and follow up of diabetic macular edema. *Semin Ophthalmol* 2003; **18**: 74–81.
- 15 Bresnick GH. Diabetic macular edema. A review. *Ophthalmology* 1986; **93**: 989–97.
- 16 Vujosevic S, Casciano M, Pilotto E, Boccassini B, Varano M, Midena E. Diabetic macular edema: fundus autofluorescence and functional correlations. *Invest Ophthalmol Vis Sci* 2011; **52**: 442–8.
- 17 Garg S, Davis RM. Diabetic retinopathy screening update. *Clin Diabetes* 2009; **27**: 140–5.
- 18 Lewis K. Improving patient compliance with diabetic retinopathy screening and treatment. *Community Eye Health* 2015; **28**: 68–9.
- 19 Kiire CA, Porta M, Chong V. Medical management for the prevention and treatment of diabetic macular edema. *Surv Ophthalmol* 2013; **58**: 459–65.
- 20 Saadine JB, Fong DS, Yao J. Factors associated with follow-up eye examinations among persons with diabetes. *Retina* 2008; **28**: 195–200.
- 21 Panch T, Szolovits P, Atun R. Artificial intelligence, machine learning and health systems. *J Glob Health*; **8**: 020303.
- 22 Rajkomar A, Oren E, Chen K, et al. Scalable and accurate deep learning with electronic health records. *NPJ digital medicine* 2018; **1**: 1–10.
- 23 Sierra-Sosa D, Garcia-Zapirain B, Castillo C, et al. Scalable healthcare assessment for diabetic patients using deep learning on multiple GPUs. *IEEE transactions on industrial informatics* 2019; **15**: 5682–9.
- 24 Alyoubi WL, Shalash WM, Abulkhair MF. Diabetic retinopathy detection through deep learning techniques: A review. *Inform Med Unlocked* 2020; **20**: 100377.
- 25 Grzybowski A, Brona P, Lim G, et al. Artificial intelligence for diabetic retinopathy screening: a review. *Eye* 2020; **34**: 451–60.
- 26 U.S. Food and Drug Administration, Center for Drug Evaluation and Research. AEYE Health K221183 approval letter, November 10, 2022. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf22/K221183.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf22/K221183.pdf).
- 27 Alsaih K, Lemaitre G, Rastgoo M, Massich J, Sidibé D, Meriaudeau F. Machine learning techniques for diabetic macular edema (DME) classification on SD-OCT images. *Biomed Eng Online* 2017; **16**: 68.
- 28 Kaymak S, Serener A. Automated age-related macular degeneration and diabetic macular edema detection on OCT images using deep learning. IEEE, 2018. DOI:10.1109/iccp.2018.8516635.
- 29 Kermany DS, Goldbaum M, Cai W, et al. Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning. *Cell* 2018; **172**: 1122–1131.e9.

- 30 Gulshan V, Peng L, Coram M, *et al.* Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. *JAMA* 2016; **316**: 2402–10.
- 31 Mo J, Zhang L, Feng Y. Exudate-based diabetic macular edema recognition in retinal images using cascaded deep residual networks. *Neurocomputing* 2018; **290**: 161–71.
- 32 Perdomo O, Ojalora S, Rodríguez F, Arevalo J, González FA. A novel machine learning model based on exudate localization to detect diabetic macular edema. In: Proceedings of the Ophthalmic Medical Image Analysis Third International Workshop. Iowa City, IA: University of Iowa, 2016.
- 33 Giancardo L, Meriaudeau F, Karnowski TP, *et al.* Exudate-based diabetic macular edema detection in fundus images using publicly available datasets. *Med Image Anal* 2012; **16**: 216–26.
- 34 Lim ST, Zaki WMDW, Hussain A, Lim SL, Kusalavan S. Automatic classification of diabetic macular edema in digital fundus images. *IEEE*, 2011. DOI:10.1109/chuser.2011.6163730.
- 35 Sahlsten J, Jaskari J, Kivinen J, *et al.* Deep Learning Fundus Image Analysis for Diabetic Retinopathy and Macular Edema Grading. *Sci Rep* 2019; **9**: 10750.
- 36 Li F, Wang Y, Xu T, *et al.* Deep learning-based automated detection for diabetic retinopathy and diabetic macular oedema in retinal fundus photographs. *Eye* 2021; published online July 1. DOI:10.1038/s41433-021-01552-8.
- 37 Diabetic Retinopathy Screening. EyePACS. 2018; published online Nov. <https://www.eyepacs.com/>.
- 38 Bresnick GH, Mukamel DB, Dickinson JC, Cole DR. A screening approach to the surveillance of patients with diabetes for the presence of vision-threatening retinopathy. *Ophthalmology* 2000; **107**: 19–24.
- 39 Litvin TV, Ozawa GY, Bresnick GH, *et al.* Utility of hard exudates for the screening of macular edema. *Optom Vis Sci* 2014; **91**: 370–5.
- 40 Decencière E, Zhang X, Cazuguel G, *et al.* Feedback on a publicly distributed image database: The Messidor database. *Image Anal Stereol* 2014; **33**: 231.
- 41 Efron B, Tibshirani RJ. An introduction to the bootstrap: CRC press. *Ekman, P, & Friesen, WV (1978) Manual for the facial action coding system* 1994.
- 42 Porwal P, Pachade S, Kamble R, *et al.* Indian diabetic retinopathy image dataset (IDRiD): a database for diabetic retinopathy screening research. *Data* 2018; **3**: 25.
- 43 Wong TY, Klein R, Islam FA, *et al.* Diabetic retinopathy in a multi-ethnic cohort in the United States. *American journal of ophthalmology* 2006; **141**: 446–55.
- 44 Mansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR. The Evolving Treatment of Diabetic Retinopathy. *Clin Ophthalmol* 2020; **14**: 653–78.

45 Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye and vision* 2015; **2**: 1–25.

46 Date RC, Shen KL, Shah BM, Sigalos-Rivera MA, Chu YI, Weng CY. Accuracy of Detection and Grading of Diabetic Retinopathy and Diabetic Macular Edema Using Teleretinal Screening. *Ophthalmol Retina* 2019; **3**: 343–9.

## Tables

Field	Images	Patients	Mean Age (SD)	Gender (% Female)	Ethnicity (fraction)
Value	32,049	15,892	55.02 (10.21)	51	White = 0.55 (Hispanic = 0.93, non-Hispanic = 0.07) ethnicity not specified = 0.13 African Descent = 0.11 Indian subcontinent origin = 0.10 Asian = 0.03 Other = 0.08

Table 1. Patient numbers and population statistics for the EyePACS dataset

DR grade	0	1	2	3	4	Ungradable
Image count	1,461	116	16,707	7,806	5,051	908
DME	0	0	8,405	4,060	2,632	498
No DME	1,461	116	8,302	3,746	2,419	410

Table 2. Patient number and DME prevalence across DR grades for the EyePACS dataset.

	Accuracy (CI)	Sensitivity (CI)	Specificity (CI)	AUC (CI)
Image level	0.889 (0.881, 0.897)	0.889 (0.878, 0.900)	0.889 (0.877, 0.900)	0.954 (0.949, 0.959)
Eye Level	0.903 (0.894, 0.912)	0.905 (0.890, 0.920)	0.902 (0.890, 0.913)	0.964 (0.958, 0.969)
Patient level	0.898 (0.886, 0.909)	0.900 (0.879, 0.917)	0.900 (0.883, 0.911)	0.962 (0.955, 0.968)

Table 3. Results for the EyePACS dataset across all three analysis levels, given in accuracy, sensitivity, specificity, and AUC with a 95% confidence interval.

DR grade	2	3	4	Ungradable
Sensitivity (CI)	0.908 (0.893, 0.921)	0.900 (0.877, 0.918)	0.899 (0.875, 0.921)	0.860 (0.784, 0.917)
Specificity (CI)	0.897 (0.881, 0.911)	0.826 (0.798, 0.880)	0.863 (0.828, 0.893)	0.920 (0.811, 0.976)
AUC (CI)	0.962 (0.956, 0.968)	0.939 (0.928, 0.949)	0.943 (0.928, 0.955)	0.961 (0.926, 0.987)

Table 4. Results on the EyePACS dataset across DR grades, given in sensitivity, specificity, and AUC with a 95% confidence interval.

	Sensitivity (CI)	Specificity (CI)	AUC (CI)
Filtered out	0.69 (0.611, 0.761)	0.858 (0.805, 0.900)	0.862 (0.819, 0.897)
Remained	0.890 (0.879, 0.901)	0.883 (0.871, 0.894)	0.952 (0.948, 0.957)


Table 5. Results for images who were filtered out and not filtered out by the image quality tool, given in accuracy, sensitivity, specificity, and AUC with a 95% confidence interval.

	Accuracy (CI)	Sensitivity (CI)	Specificity (CI)	AUC (CI)
Sahlsten et al <sup>35</sup>	0.931 (0.915, 0.944)	0.69 (0.626, 0.750)	0.989 (0.980, 0.994)	0.932 (0.917, 0.946)
Li et al <sup>36</sup>	-	0.886 (0.881, 0.892)	0.908 (0.898, 0.912)	0.948 (0.943, 0.951)
Proposed, image level	0.943 (0.927, 0.955)	0.875 (0.811, 0.922)	0.954 (0.939, 0.967)	0.971 (0.955, 0.982)
Proposed, patient level	0.925 (0.898, 0.944)	0.897 (0.820, 0.947)	0.932 (0.905, 0.953)	0.964 (0.936, 0.979)

Table 6. Comparison between the proposed method and previous works on the Messidor-2 dataset, given in accuracy, sensitivity, specificity, and AUC with a 95% confidence interval. Additionally, results on the patient level (not done in previous works) are given.







12260279

